Disruption or excision of provirus as an approach to HIV cure

AIDS Patient Care and STDs

Volumn 30, Issue 12, 2016, Pages 551-555

  Jerome, Keith R ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CRISPR Cas9; Endonuclease; Gene editing; Gene therapy; HIV cure; Provirus

Indexed keywords

ENDONUCLEASE; VIRUS VECTOR; VIRUS DNA; ZINC FINGER PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIRAL CLEARANCE; VIRAL GENE DELIVERY SYSTEM; VIRUS RESISTANCE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENE THERAPY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; METABOLISM; PROCEDURES; PROVIRUS; VIROLOGY;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DNA, VIRAL; ENDONUCLEASES; GENETIC THERAPY; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; PROVIRUSES; ZINC FINGERS;

EID: 85002755328     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2016.0232     Document Type: Article

References (30)

1. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013;9:e1003174.
2. Crooks AM, Bateson R, Cope AB, et al. Precise quantita-tion of the latent HIV-1 reservoir: Implications for eradication strategies. J Infect Dis 2015;212:1361-1365.
3. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155:540-551.
4. Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A 2014;111: 13475-13480.
5. Conway JM, Perelson AS. Post-treatment control of HIV infection. Proc Natl Acad Sci U S A 2015;112:5467-5472.
6. Henrich TJ, Hu ZX, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207:1694-1702.
7. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
8. June CH, Levine BL. T cell engineering as therapy for cancer and HIV: Our synthetic future. Philos Trans R Soc Lond B Biol Sci 2015;370:20140374.
9. Spragg C, De Silva Feelixge H, Jerome KR. Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS 2016;11:442-449.
10. Aubert M, Madden EA, Loprieno M, et al. In vivo disruption of latent HSV by designer endonuclease therapy. JCI Insight 2016;1:e88468.
11. Kaminski R, Bella R, Yin C, et al. Excision of HIV-1 DNA by gene editing: A proof-of-concept in vivo study. Gene Ther 2016;23:690-695.
12. Zhou Q, Uhlig KM, Muth A, et al. Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors. J Immunol 2015;195:2493-2501.
13. Aubert M, Ryu BY, Banks L, Rawlings DJ, Scharenberg AM, Jerome KR. Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One 2011;6:e16825.
14. Sedlak RH, Liang S, Niyonzima N, et al. Digital detection of endonuclease mediated gene disruption in the HIV provirus. Sci Rep 2016;6:20064.
15. Zhu W, Lei R, Le Duff Y, et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 2015; 12:22.
16. Aubert M, Boyle NM, Stone D, et al. In vitro inactivation of latent HSV by targeted mutagenesis using an HSV-specific homing endonuclease. Mol Ther Nucleic Acids 2014;3:e146.
17. Certo MT, Gwiazda KS, Kuhar R, et al. Coupling endo-nucleases with DNA end-processing enzymes to drive gene disruption. Nat Methods 2012;9:973-975.
18. Qu X, Wang P, Ding D, et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res 2013;41:7771-7782.
19. Ebina H, Kanemura Y, Misawa N, et al. A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS One 2015;10:e0120047.
20. Hu W, Kaminski R, Yang F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A 2014;111:11461-11466.
21. Liao HK, Gu Y, Diaz A, et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun 2015;6:6413.
22. Dampier W, Nonnemacher MR, Sullivan NT, Jacobson JM, Wigdahl B. HIV excision utilizing CRISPR/Cas9 technology: Attacking the proviral quasispecies in reservoirs to achieve a cure. MOJ Immunol 2014;1:pii:00022.
23. Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR. Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 2012;86:8920-8936.
24. Schiffer JT, Swan DA, Stone D, Jerome KR. Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: A mathematical modeling approach. PLoS Comput Biol 2013;9:e1003131.
25. De Silva Feelixge HS, Stone D, Pietz HL, et al. Emergence of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res 2016;126:90-98.
26. Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther 2016;24:522-526.
27. Yoder KE, Bundschuh R. Host double strand break repair generates HIV-1 strains resistant to CRISPR/Cas9. Sci Rep 2016;6:29530.
28. Wang Z, Pan Q, Gendron P, et al. CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep 2016;15:481-489.
29. Kiem HP, Jerome KR, Deeks SG, McCune JM. Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 2012;10:137-147.
30. Stone D, Niyonzima N, Jerome KR. Genome editing and the next generation of antiviral therapy. Hum Genet 2016; 135:1071-1082.